Vaginally administered Oxytocin investigated to reverse postmenopausal vaginal atrophy by promoting mucosal cell proliferation

Up to 50% of postmenopausal women suffer from vaginal atrophy, characterized by dryness, irritation, and discomfort, often making intercourse painful. This condition stems from a lack of estrogen, leading to a higher vaginal pH and increased susceptibility to infections. The mucosal epithelium shows severe senile atrophy, with an increased number of basal and parabasal cells and a reduced number of superficial cells. Unlike other menopausal symptoms, vaginal issues often worsen with age. Oxytocin, a peptide hormone known for its roles in reproduction, has shown positive effects on the proliferation of human vaginal mucosal cells from postmenopausal women, suggesting its potential to directly stimulate new cell formation or increase growth factor production.

This study aims to investigate the dose-relationship of topically administered Vagitocin (oxytocin) on the vaginal mucosal membrane in postmenopausal women. The primary objective is to assess the reversal of vaginal atrophy, as measured by cytological examination of the vaginal mucosal epithelium. The primary endpoint is the change (%) in superficial cells, specifically the Maturation Value (MV), up to 7 weeks and 12 weeks after baseline. The study design involves treatment over 12 weeks and includes a placebo comparator arm, implying a randomized, controlled trial structure, though specific doses, frequency, or the total number of participants are not detailed in the abstract.

The provided abstract outlines the study's objectives and background but does not present any results or findings. Therefore, no specific numbers, percentages, p-values, or fold-changes from the intervention can be reported at this time. The study aims to determine if topical oxytocin can reverse vaginal atrophy, as assessed by cytological examination and changes in the Maturation Value (MV) of vaginal mucosal cells. The primary outcome measure is the change in the percentage of superficial cells over a period of up to 7 to 12 weeks of treatment. Without the study's completion or published results, the efficacy or dose-response of vaginally administered oxytocin for postmenopausal vaginal atrophy remains to be determined.